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Abstract 
Paradoxically, N-methyl-D-aspartate (NMDA) receptor antagonists are both used to 
model certain aspects of schizophrenia and to treat refractory depression. However, the 
role of different subunits of the NMDA receptor in both conditions is poorly 
understood. Here we used biochemical and behavioral readouts to examine the in vivo 
prefrontal efflux of serotonin and glutamate as well as the stereotypical behavior and the 
antidepressant-like activity in the forced swim test elicited by antagonists selective for 
the GluN2A (NVP-AAM077) and GluN2B (Ro 25-6981) subunits. The effects of the 
non subunit selective antagonist, MK-801; were also studied for comparison. The 
administration of MK-801 dose-dependently increased the prefrontal efflux of serotonin 
and glutamate and markedly increased the stereotypy scores. NVP-AAM077 also 
increased the efflux of serotonin and glutamate, but without the induction of 
stereotypies. In contrast, Ro 25-6981 did not change any of the biochemical and 
behavioral parameters tested. Interestingly, the administration of NVP-AAM077 and Ro 
25-6981 alone elicited antidepressant-like activity in the forced swim test, in contrast to 
the combination of both compounds, which evoked marked stereotypies. Our 
interpretation of the results is that both GluN2A and GluN2B subunits are needed to 
induce stereotypies, which might be suggestive of potential psychotomimetic effects in 
humans, but the antagonism of only one of these subunits is sufficient to evoke an 
antidepressant response. We also propose that GluN2A receptor antagonists could have 
potential antidepressant activity in the absence of potential psychotomimetic effects. 
 
Keywords: schizophrenia; depression; animal model; NMDA receptor; GluN2 subunits 
 
 
 
 
NPP-14-0365R 
3 
 
 
INTRODUCTION 
It is well established that N-methyl-D-aspartate (NMDA) receptors play a key role in 
several psychiatric disorders and their pharmacological treatments. For instance, 
schizophrenia has been associated with NMDA receptor hypofunction insofar as the 
administration of NMDA receptor antagonists can evoke positive and negative 
symptoms as well as characteristic cognitive deficits closely resembling those of the 
illness (Javitt and Zukin, 1991; Krystal et al, 1994). In rodents, NMDA receptor 
antagonists cause hyperlocomotion and stereotypies (Homayoun et al, 2004; López-Gil 
et al., 2012), behaviors that have been potentially related to positive symptoms of 
schizophrenia (Lipska and Weinberger, 2003; Sams-Dodd, 1997), and are thought to 
result from excessive dopaminergic and serotonergic activities (Jentsch et al, 1998; 
Lucki, 1998). In addition to these behavioral changes, NMDA receptor antagonists also 
augment the release of dopamine (Moghaddam et al., 1997), glutamate and serotonin (5-
hydroxytryptamine, 5-HT) in the medial prefrontal cortex (mPFC) of rats (Amargós-
Bosch et al., 2006; López-Gil et al. 2007, 2012). It is postulated that this increased 
release of glutamate in the mPFC stimulates prefrontal output to brainstem 
monoaminergic nuclei, thereby increasing monoaminergic cell firing and prefrontal 
monoamine efflux (López-Gil et al., 2007). From a molecular viewpoint, NMDA 
receptors are tetrameric structures assembled from two obligatory GluN1 subunits and 
two GluN2A (formerly NR2A) or GluN2B (formerly NR2B) subunits. However, 
triheteromers formed by GluN1/GluN2A/GluN2B subunits are also abundant in the 
neocortex and hippocampus of the adult rodent brain (Traynelis et al., 2010). Despite 
the widespread use of acute NMDA receptor antagonism to model schizophrenia (Adell 
et al., 2012), the contribution of GluN2 subunits to the biochemical and behavioral 
changes elicited by NMDA receptor antagonists is poorly understood. In this regard, 
there is one study reporting that the GluN2B, rather than GluN2A, subunit substituted 
for the disruption of prepulse inhibition (PPI) of the startle response and hyperactivity 
induced by the NMDA receptor antagonist phencyclidine (Chaperon et al., 2003). In 
addition, Ro 25-6981 was found to disinhibit hippocampal pyramidal neurons by 
reducing GABAergic output (Hanson et al., 2013), a feature also know to model 
psychosis (Lisman et al., 2008). Therefore, it appears that the blockade of the GluN2B 
subunit is sufficient to elicit psychotomimetic activity. 
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In the field of mood disorders, NMDA receptor blockers are of particular 
relevance for treatment-resistant depression (Skolnick et al., 2009). Indeed, there is 
compelling evidence that the NMDA receptor antagonist, ketamine, evokes rapid 
(within 2 h) and robust antidepressant effects that can last for a week (Berman et al., 
2000; Zarate et al., 2006a). Interestingly, the same doses of ketamine that evoke 
psychotic symptoms also produce antidepressant effects. It is possible that psychosis is 
an immediate consequence of NMDA receptor blockade and reflects, in part, the ability 
of these drugs to stimulate glutamate release (Moghaddam et al., 1997; López-Gil et al., 
2007). However, a component of the antidepressant response seems to be a delayed 
consequence of the glutamate released by ketamine that would stimulate AMPA 
receptors (Maeng et al., 2008; Koike et al., 2011; Akinfiresoye and Tizabi, 2013). Thus, 
both effects are mechanistically associated but temporally dissociated. 
Due to these adverse side effects of ketamine, much research is focused in 
improving the pharmacological profile of NMDA receptor antagonists by investigating 
whether subtype-selectivity could achieve a better therapeutic index. In this regard, 
preclinical studies have shown that the GluN2B receptor antagonist, Ro 25-6981, 
possesses antidepressant-like effects (Maeng et al., 2008; Li et al., 2010). On the other 
hand, inactivation of the GluN2A has also been shown to evoke antidepressant-like 
activity in mice (Boyce-Rustay and Holmes, 2006). Furthermore, in the clinic several 
investigational drugs have manifested some efficacy in the treatment of depressive 
states, such as the GluN2B receptor antagonists CP-101,606 (Preskorn et al., 2008) and 
MK 0657 (Ibrahim et al., 2012), the NMDA receptor glycine-site partial agonist GLYX-
13 (Burgdorf et al., 2013), and the low-trapping nonselective NMDA channel blocker 
AZD6765 (Sanacora et al., 2013; Zarate et al., 2013). However, while the rapid and 
robust effects of ketamine are clear, by comparison the effects of MK 0657 and 
AZD6765 are modest and short-lived. In contrast, memantine, a NMDA channel 
blocker with similarity to ketamine, appears not to possess antidepressant effects when 
administered alone (Zarate et al., 2006b), which might be due to its unusual binding 
properties (Chen and Lipton, 2005), and not be representative of NMDA channel 
blockers as a whole. In addition, CP-101,606 did produce severe dissociative effects in 
depressed patients (Preskorn et al., 2008). Therefore, the results of clinical studies are 
not consistent with the notion that GluN2B antagonists may have a better profile than 
channel blockers like ketamine. 
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Overall, GluN2A and GluN2B receptor subunits may be anatomically and 
functionally segregated and play distinct roles in the regulation of prefrontal synaptic 
response to different inputs carrying contextual and affective information. Thus, it has 
been proposed that afferents from ventral hippocampus may preferentially synapse onto 
postsynaptic sites containing GluN2B subunits whereas projections from basolateral 
amygdala may preferentially synapse onto postsynaptic sites containing GluN2A 
subunits (Flores-Barrera et al., 2014). In the present study we sought to examine the 
effects of GluN2A and GluN2B subunits in the acute NMDA receptor antagonist model 
of schizophrenia as well as in the treatment of depression-like effects in the rat. To this 
end, we have assessed the biochemical and behavioral changes elicited by NVP-
AAM077 (Auberson et al., 2002), a competitive antagonist showing ca. 10-fold 
selectivity for the rat GluN2A subunit compared to the GluN2B subunit (Neyton and 
Paoletti, 2006), and Ro 25–6981, which is about 5000-fold selective for GluN2B over 
GluN2A (Fischer et al., 1997). The results are compared with the effects of a 
nonselective NMDA receptor channel blocker such as dizocilpine (MK-801). The 
antidepressant-like effects were measured in the forced swim test (FST), while the 
possible emergence of psychotomimetic adverse effects was associated with the ability 
to induce stereotypical behavior. 
 
MATERIALS AND METHODS 
Animals 
Male Wistar rats (Charles River Laboratories, Cerdanyola del Vallès, Spain) weighing 
280–350 g were used. Food and water were always available. All experimental 
procedures followed European Union regulations (Official Journal of the European 
Communities L358/1, 18 December 1986), and were approved by the Institutional 
Animal Care and Use Committee.  
Drugs and Reagents 
Serotonin (5-hydroxytryptamine oxalate, 5-HT), glutamate, MK-801 and o-
phthaldialdehyde (OPA) reagent (containing 1 mg OPA per ml solution with 2-
mercaptoethanol as the sulphydryl moiety) were purchased from Sigma-Aldrich (Tres 
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Cantos, Spain). Citalopram hydrobromide and Ro 25-6981 were purchased from Tocris 
(Bristol, UK). NVP-AAM077 was obtained from Novartis (Basel, Switzerland). MK-
801 and Ro 25-6981were dissolved in saline and 50% dimethyl sulfoxide (DMSO), 
respectively. NVP-AAM077 was dissolved in NaOH 0.1 M, then the pH was raised to 
~7 with HCl 0.1 M and taken to a final dilution with distilled water. All drugs were 
injected intraperitoneally (i.p.). Appropriate vehicles were administered as the 
respective control groups. 
Intracerebral Microdialysis 
Concentric dialysis probes with a 4-mm membrane length were implanted under sodium 
pentobarbital anesthesia (60 mg/kg i.p.) in the mPFC (AP +3.2 mm, L ±0.6 mm, DV -
6.0 mm; from bregma), according to Paxinos and Watson (2005). A representative 
histological section showing the location of the concentric dialysis probe in the mPFC is 
illustrated in Figure S1. In all cases, microdialysis experiments were conducted 24 h 
after surgery in freely moving rats by continuously perfusing probes with aCSF (125 
mM NaCl, 2.5 mM KCl, 1.26 mM CaCl2, 1.18 mM MgCl2, and 1 µM citalopram) at a 
rate of 1.5 µl/min. Dialysate samples of 30 µl were collected every 20 min, and 5-HT 
and glutamate were determined by HPLC. At the completion of dialysis experiments, 
rats were given an overdose of sodium pentobarbital and a Fast Green solution was 
perfused through the dialysis probes to stain the surrounding tissue. 
Biochemical Analysis 
The concentration of 5-HT in dialysate samples was determined by an HPLC system as 
described (López-Gil et al., 2007). It consisted of a Waters 717plus autosampler 
(Waters Cromatografia, Cerdanyola, Spain), a Hewlett-Packard series 1050 pump 
(Agilent Technologies, Las Rozas, Spain), a 3-µm octadecylsilica (ODS) column (7.5 
cm x 0.46 cm; Beckman, San Ramon, CA), and an amperometric detector Hewlett-
Packard 1049 (Agilent Technologies) set at an oxidation potential of 0.6 V. The mobile 
phase consisted of 0.15 M NaH2PO4, 1.8 mM octyl sodium sulfate, 0.2 mM EDTA (pH 
2.8, adjusted with phosphoric acid), and 30% methanol and was pumped at 0.7 ml/min. 
For the determination of glutamate, another HPLC system was used, which consisted of 
a Waters 717plus autosampler, a Waters 600 quaternary gradient pump, and a Nucleosil 
5-µm ODS column (10 cm x 0.4 cm; Teknokroma, Spain). Dialysate samples were 
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precolumn derivatized with OPA reagent and all this process was carried out by the 
autosampler. Briefly, 90 µl distilled water was added to the 10 µl dialysate sample and 
this was followed by the addition of 15 µl of the OPA reagent. After 2.5 min reaction, 
80 µl of this mixture was injected into the column. Detection was carried out with a 
Waters 470 Scanning Fluorescence Detector using excitation and emission wavelengths 
of 360 nm and 450 nm, respectively. The mobile phase was pumped at 0.8 ml/min and 
consisted of two components: Solution A, made up of 0.05 M Na2HPO4, 28% methanol, 
adjusted to pH 6.4 with 85% H3PO4, and solution B, made up of methanol/H2O (8:2 
ratio). After elution of the glutamate peak at 3 min with 100% solution A, a gradient 
was established going from 100% solution A to 100% solution B in 2 min. After 
washing out late eluting peaks (3 min), the mobile phase returned to initial conditions 
(100% solution A) in 2 min. The detection limits for 5-HT and glutamate were 4 fmol 
and 0.3 pmol, respectively (signal-to-noise ratio 3). 
Behavioral Measures 
Gross behavioral scores were assessed by direct observation of rats undergoing in vivo 
microdialysis and were based on a method described previously (Jackson et al. 2004). 
Stereotypies were rated during the last 5 min of each 20-min sample. Animals received 
a score of 0 (absence), 1 (presence) or 2 (intense >50% of the 5-min block) for each of 
the following motor stereotypies commonly associated with NMDA antagonism: 
reciprocal forepaw treading, side-to-side head weaving, and hyperlocomotion (turning). 
Total scores for each rat were calculated by summing the individual values of each 
behavior during each 5-min period. 
Before FST was conducted, rats were handled daily for 1 week for habituation. 
On day 1 (pretest), rats were placed in a clear plexyglas cylinder (46 cm height, 20 cm 
diameter) filled with 24 ± 1°C water to a height of 30 cm, for 15 min. After this pretest, 
animals were returned to their home cages and dried under a lamp for 30 min. The test 
was conducted 24 h after the pretest session in the same cylinder for 5 min, and was 
videotaped (Videotrack, View Point, Lyon, France). The 5-min test session was divided 
into 5-s epochs. At the end of each epoch the predominant behavior was rated as 
immobility, climbing and swimming by an experimenter blind to the treatment. Since 
these drugs allegedly possess a fast antidepressant action and display similar 
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pharmacokinetic profiles in microdialysis studies (Mabrouk et al., 2013), their 
administration was carried out 20 min before the test session. 
General locomotor activity was measured in independent groups of animals in an 
open field arena (100 cm x 100 cm x 40 cm) with black plastic walls dimly lighted. As 
for the FST, 20 min after drug administration, ambulation was recorded during 15 min 
by a video camera connected to a computer (Videotrack) and expressed as the distance 
traveled (cm) in 15 min. 
 
Statistics 
Data are expressed as mean ± SEM. One or two-way analysis of variance (ANOVA) 
followed by post-hoc Newman-Keuls multiple comparisons test was used to analyze 
differences among three or more independent groups. In all cases the level of 
significance was set at p < 0.05. 
 
RESULTS 
5-HT and glutamate efflux in the mPFC 
Two-way ANOVA showed that the administration of MK-801 (0.1–1 mg/kg, i.p.) 
enhanced dose dependently the extracellular concentration of 5-HT (Figure 1a) as 
demonstrated by the significant effect of treatment (F4,25 = 4.83, p = 0.005027), time 
(F9,225 = 7.24, p = 0.0001), but not treatment x time interaction (F36,225 = 1.23, p = 
0.182942). Post hoc comparisons (Newman–Keuls test) showed each dose of MK-801 
elevated extracellular 5-HT (p = 0.043335, 0.1 mg/kg; p = 0.012458, 0.2 mg/kg; p = 
0.001491, 0.5 mg/kg; p = 0.000153, 1 mg/kg). The increase of prefrontal 5-HT elicited 
by the dose of 1 mg/kg MK-801 was higher than that of 0.1 and 0.2 mk/kg MK-801 (p = 
0.003202 and p = 0.018113, respectively). The systemic administration of MK-801 also 
increased extracellular glutamate (Figure 1b), as shown by the significant effect of 
treatment (F4,25 = 10.91, p = 0.000029), time (F9,225 = 11.86, p = 0.00001), and treatment 
x time interaction (F36,225 = 6.55, p = 0.00001). However, only the dose of 1.0 mg/kg 
MK-801 significantly increased dialysate glutamate concentration (p < 0.0005 with 
respect to all other doses; Newman–Keuls test). 
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Similar effects were observed with the GluN2A subunit selective NVP-
AAM077. Thus, two-way ANOVA showed that the administration of NVP-AAM077 
(2.5-20 mg/kg, i.p.) increased the extracellular concentration of 5-HT (Figure 2a) as 
demonstrated by the significant effect of treatment (F4,27 = 6.83, p = 0.000620), time 
(F9,243 = 6.68, p = 0.00001), and treatment x time interaction (F36,243 = 2.46, p = 
0.000028). Post hoc comparisons showed that the higher doses of NVP-AAM077 (10 
and 20 mg/kg) increased 5-HT levels (p = 0.014584 and p = 0.002951, respectively, 
Newman–Keuls test). The systemic administration of NVP-AAM077 also increased 
extracellular glutamate (Figure 2b), as shown by the significant effect of treatment (F4,27 
= 3.99, p = 0.011408). However, the effects of time (F9,243 = 1.18, p = 0.310293) and the 
interaction x time (F36,243 = 1.37, p = 0.088482) for glutamate did not show significant 
differences. Post hoc comparisons showed that only the highest dose of 20 mg/kg was 
able to increase the concentration of glutamate (p = 0.026992, Newman–Keuls test). 
In contrast to nonselective (MK-801) and GluN2A subunit selective (NVP-
AAM077) NMDA receptor antagonists, the GluN2B subunit selective antagonist, Ro 
25-6981, did not exert any influence on the extracellular concentrations of 5-HT and 
glutamate at any of the doses tested (Figure 3). 
 
Stereotypy Scores 
As shown in Figure 4, one-way ANOVA showed that the administration of the three 
NMDA receptor antagonists had a significant effect on the stereotypy scores (F6,42 = 
43.02, p = 0.0001). Post hoc comparisons, however, indicated that only MK-801 (p < 
0.001, Newman–Keuls test) and the combination of NVP-AAM077 and Ro 25-6981 (p 
< 0.05, Newman–Keuls test) induced marked stereotypies at the doses tested. In 
contrast, both NVP-AAM077 and Ro 25-6981 alone produced virtually no stereotypy. 
 
Antidepressant-like effects in the FST 
The acute administration of the three NMDA receptor antagonists studied had 
significant effects on immobility (F4,32 = 7.81, p = 0.000165), climbing (F4,32 = 7.51, p = 
0.000212) and swimming (F4,32 = 4.12, p = 0.008372) behaviors measured in the FST 
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(Figure 5a). Post hoc comparisons showed that the the three agents reduced immobility, 
but only the subunit selective inhibitors (NVP-AAM077 and Ro 25-6981) increased 
climbing (p < 0.05, Newman–Keuls test). At the dose tested (0.1 mg/kg), the MK-801-
induced reduction of immobility and increase in swimming was not suggestive of a true 
antidepressant-like effect, but rather of an enhanced general locomotor activity as 
depicted in Figure 5b (F4,29 = 10.53, p < 0.0001). Post-hoc comparisons showed that 
MK-801 evoked hyperlocomotion (p < 0.01, Newman–Keuls test) whereas the other 
agents did not alter locomotor activity. 
 
DISCUSSION 
The main findings of this work are: first, both NVP-AAM077 and Ro 25-6981 
possess antidepressant-like activity and second, neither of these compounds alone 
exhibit psychotomimetic-like activity at the doses tested, but they did so when 
administered together. This and previous work from our lab demonstrated that the 
noncompetitive NMDA receptor antagonist, MK-801 induced stereotypies that were 
accompanied by an increased release of glutamate and 5-HT in the mPFC (López-Gil et 
al., 2007). MK-801 is a NMDA channel blocker that is not subunit selective although it 
inhibits NMDA receptors containing the GluN2A subunit faster than those containing 
the GluN2B subunit (Gielen et al., 2009). Therefore, the question remained as to 
whether the MK-801-induced behavioral and biochemical effects were dependent on 
any specific GluN2 subunit. The present results show that the blockade of the GluN2A 
subunit is sufficient to evoke an enhanced release of glutamate and 5-HT, but suggests 
that blockade of both GluN2A and GluN2B subunits are necessary for stereotypical 
behavior to emerge. Our results are at odds with clinical observations showing that the 
sole blockade of the GluN2B subunit is sufficient to induce dissociative effects in 
depressed patients (Preskorn et al., 2008). The lack of effect of Ro 25-6981 could be 
due to an insufficient dosage or it is also possible that a transient surge in either 5-HT or 
glutamate in the mPFC could have been missed because of dilution effects in the 20-
min dialysate sample. Alternatively, the effects of Ro 25-6981 may be area specific 
because it has been reported that this compound increases dialysate glutamate in other 
brain areas such as the globus pallidus (Mabrouk et al., 2013). Furthermore, it is also 
known that stereotypies produced by MK-801 do not result from changes in prefrontal 
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cortex activity (López-Gil et al., 2012). On the other hand, although NVP-AAM077 
failed to evoke stereotypical behavior, it has been reported that it can disrupt spatial 
learning (Hu et al., 2009), working memory (Smith et al., 2011) and increase aberrant 
gamma activity (Kocsis, 2012). Thus, it would seem at first sight that the blockade of 
the GluN2A subunit may contribute to cognitive deficits induced by NMDA receptor 
antagonists, but dissociative effects may be rather associated with GluN2B antagonists. 
However, recent studies showed that AZD6765, a non-selective, low-affinity NMDA 
receptor antagonist has minimal dissociative effects (Sanacora et al., 2013; Zarate et al., 
2013). This would suggest that the mechanisms that mediate the psychotomimetic 
effects are more complicated than simply resulting from the inhibition of a specific 
GluN2 subunit, and may rather be related to actions on specific circuits in the brain. 
The next step in the present study was to examine whether the selective blockade 
of GluN2A or GluN2B subunits was equally effective in producing an antidepressant 
response. MK-801 was shown before to display antidepressant-like effects without 
altering locomotor activity, but at lower doses (0.05 mg/kg) than those tested in the 
present study (Maeng et al., 2008). Previous work had already demonstrated that Ro 25-
6981 possessed antidepressant-like properties in the FST, the novelty-suppressed 
feeding test (NFST) and the deficit in sucrose consumption elicited by chronic 
unpredictable stress (Li et al., 2010, 2011). In rodents, these antidepressant effects are 
hypothesized to result from glutamate release and AMPA receptor activation (Li et al., 
2010; Maeng et al., 2008). 
In the clinic, GluN2B receptor antagonists have shown efficacy in treating 
depression (Preskorn et al., 2008; Ibrahim et al., 2012). Furthermore, a genome-wide 
association study evidenced alterations in the gene encoding the GluN2B subunit, 
GRIN2B, in depression (Aragam et al., 2013) and recent work revealed that GRIN2B 
confers susceptibility to treatment-resistant depression (Zhang et al., 2014). Postmortem 
studies, however, have yielded discrepant results with no changes (Duric et al., 2013) or 
decreased expression of GluN2A and GluN2B in depression (Feyissa et al., 2009). It is 
possible that differences in the brain region examined or in subunit expression ratio 
account for such discrepancies. However, to the best of our knowledge, no GluN2A 
receptor antagonist is under evaluation for this pathological condition. Only one study 
has reported that the genetic inactivation of the GluN2A subunit induces anxiolytic- and 
antidepressant-like effects in mice (Boyce-Rustay and Holmes, 2006). Our results 
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confirmed the antidepressant-like action of Ro 25-6981 and preliminarily extended this 
effect to the blockade of the GluN2A receptor subunit by NVP-AAM077. Furthermore, 
the acute increase in glutamate induced by NVP-AAM077 and its action on AMPA 
receptors can contribute to the release of BDNF and subsequent increase in 
synaptogenesis (Duman and Aghajanian, 2012), and synaptic plasticity (Maeng et al., 
2008), which may be suggestive of an effective antidepressant action. Importantly, the 
lack of stereotypical behavior suggests that both Ro 25-6981 and NVP-AAM077 have 
the potential to show antidepressant effects without evoking psychotomimetic effects. 
Thus, independent blockade of either GluN2A or GluN2B subunits may show promise 
in the treatment of refractory depression, with a similar or better safety profile than 
nonselective NMDA receptor antagonists such as ketamine. Nevertheless, ketamine 
exhibits a faster onset of antidepressant response than GluN2B receptor antagonists (2 h 
vs. 2-5 days). In constrast, GluN2A receptor antagonists could have a faster onset of 
therapeutic action because NMDA receptors containing GluN2A subunits possess a 
higher probability of channel opening (Gielen et al., 2009) and/or inducing changes in 
cortical 5-HT and glutamate. The role of GluN2B subunit is not limited to the 
modulation or prefrontal recurrent excitatory activity, which is implicated in negative 
symptoms (Wang et al., 2013). Both behavioral and electrophysiological studies have 
recently shown that the GluN2B-mediated transmission is critical for sustaining 
hippocampal-to-prefrontal cortex function and plasticity (Gilmartin et al., 2013; Flores-
Barrera et al., 2014). 
In summary our results show that the blockade of both subunits is necessary to 
develop psychotic-like effects whereas the blockade of one of these subunits is 
sufficient to elicit an antidepressant-like action in the FST. Further research is needed to 
confirm the potential antidepressant efficay of selective GluN2A receptor antagonists as 
well as abuse liability and cognitive impairment after chronic exposure. 
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FIGURE LEGENDS 
 
Figure 1. Effects of systemic administration of 0.1, 0.2, 0.5, and 1 mg/kg of MK-801 
(arrow) on the efflux of 5-HT (a) and glutamate (b) in the mPFC. Data (mean ± SEM) 
are expressed as percentage changes of the four basal pretreatment values. Number of 
animals is given in parentheses. The control group received one injection of saline 
(arrow). *p < 0.05, **p < 0.005, ***p < 0.0005, Newman-Keuls test following 
ANOVA. 
 
Figure 2. Effects of systemic administration of 2.5, 5, 10, and 20 mg/kg of NVP-
AAM077 (arrow) on the efflux of 5-HT (a) and glutamate (b) in the mPFC. Data (mean 
± SEM) are expressed as percentage changes of the four basal pretreatment values. 
Number of animals is given in parentheses. The control group received one injection of 
vehicle (arrow). *p < 0.05, **p < 0.005, Newman-Keuls test following ANOVA. 
 
Figure 3. Effects of systemic administration of 2.5, 5, 10, and 20 mg/kg of Ro 25-6981 
(arrow) on the efflux of 5-HT (a) and glutamate (b) in the mPFC. Data (mean ± SEM) 
are expressed as percentage changes of the four basal pretreatment values. Number of 
animals is given in parentheses. The control group received one injection of vehicle 
(arrow). 
 
Figure 4. Effects of systemic administration of MK-801 (0.1 and 0.5 mg/kg), Ro 25-
6981 (10 mg/kg), NVP-AAM077 (10 and 20 mg/kg) and the combination (NVP + Ro) 
of NVP-AAM077 (20 mg/kg) and Ro 25-6981 (20 mg/kg) on stereotypy scores. Both 
doses of MK-801 and NVP + Ro significantly increased stereotypies (turning, forepaw 
treading, head weaving) in rats. Systemic administration of Ro 25-6981 and NVP-
AAM077 did not induce stereotypies. Behavioral scores are expressed as mean ± SEM. 
*p < 0.05, **p < 0.001, Newman–Keuls test following ANOVA. 
 
Figure 5. Effects of systemic administration of MK-801 (0.1 mg/kg), Ro 25-6981 (10 
mg/kg) and NVP-AAM077 (10 and 20 mg/kg) on immobility, climbing and swimming 
behaviors in the FST (a) and on locomotor activity in an open field (b). Data are 
expressed as mean ± SEM. The three agents reduced immobility, but only Ro 25-6981 
and NVP-AAM077 increased climbing. Swimming was increased only by MK-801 and 
Ro 25-6981. *p < 0.05, **p < 0.001, Newman–Keuls test following ANOVA. MK-801 
(0.1 mg/kg) induced an increase in general locomotor activity (*p < 0.01, Newman–
Keuls test following ANOVA). 





